Ionpath, Inc. operates in the biotechnology sector, specializing in high definition spatial proteomics. The company has developed a multiplexed ion beam imaging (MIBI) platform that surpasses traditional immunohistochemistry (IHC) methods. This platform enables researchers and clinicians to gain a deeper understanding of the tissue microenvironment through highly multiplexed, quantitative single cell analysis. Ionpath's technology is particularly valuable for identifying responder populations, predicting patient responses, and informing therapeutic selection. The company's primary clients include academic research institutions, pharmaceutical companies, and clinical laboratories. Ionpath generates revenue through the sale of its imaging platforms, consumables, and related services. The market it operates in is the rapidly growing field of precision medicine and advanced diagnostics.

Keywords: spatial proteomics, tissue imaging, single cell analysis, multiplexed ion beam imaging, tumor microenvironment, quantitative analysis, clinical grade repeatability, therapeutic selection, biotechnology, precision medicine.